Cargando…

Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines

Although drug-resistant HIV variants are considered to be less fit than drug-susceptible viruses, replication competence of these variants harbored by patients has not yet been elucidated in detail. We herein assessed the replication competence of strains obtained from individuals receiving antiretr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kageyama, Seiji, Amolong Hinay, Alfredo, Telan, Elizabeth Freda Omengan, Samonte, Genesis May Jopson, Leano, Prisca Susan Agustin, Tsuneki-Tokunaga, Akeno, Kanai, Kyosuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748504/ https://www.ncbi.nlm.nih.gov/pubmed/31216920 http://dx.doi.org/10.1177/2325958219856579

Ejemplares similares

In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs
por: Hinay, Alfredo A., et al.
Publicado: (2022)

Pro-Inflammatory Cytokines and Interferon-Stimulated Gene Responses Induced by Seasonal Influenza A Virus with Varying Growth Capabilities in Human Lung Epithelial Cell Lines
por: Hinay, Alfredo A., et al.
Publicado: (2022)

Growth capability of epidemic influenza viruses in Japan since the 2009 H1N1 pandemic
por: Tsuneki-Tokunaga, Akeno, et al.
Publicado: (2021)

Brain antioxidants and hippocampal microanatomical alterations following the administration of Efavirenz/Lamivudine/Tenofovir disoproxil fumarate and Lamivudine/Nevirapine/Zidovudine in adult male Wistar rats
por: Edagha, Innocent A., et al.
Publicado: (2022)

Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine versus Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia
por: Sorsa, Abebe
Publicado: (2018)

Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus
por: Cong, Yu, et al.
Publicado: (2016)

Foetal Loss and Enhanced Fertility Observed in Mice Treated with Zidovudine or Nevirapine
por: Onwuamah, Chika K., et al.
Publicado: (2014)

Frequent Detection of Anti-Tubercular-Glycolipid-IgG and -IgA Antibodies in Healthcare Workers with Latent Tuberculosis Infection in the Philippines
por: Siddiqi, Umme Ruman, et al.
Publicado: (2012)

Exposure of Allium cepa Root Cells to Zidovudine or Nevirapine Induces Cytogenotoxic Changes
por: Onwuamah, Chika K., et al.
Publicado: (2014)

Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)
Publicado: (2008)

Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss
por: van Vonderen, Marit G. A., et al.
Publicado: (2009)

Quality by Design Optimization of Cold Sonochemical Synthesis of Zidovudine-Lamivudine Nanosuspensions
por: Witika, Bwalya A., et al.
Publicado: (2020)

Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand
Publicado: (2016)

Lamivudine and Zidovudine-Loaded Nanostructures: Green Chemistry Preparation for Pediatric Oral Administration
por: Guedes, Marina D. V., et al.
Publicado: (2023)

The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes
por: Gray, Lachlan R., et al.
Publicado: (2013)

N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance
por: Yap, Soo-Huey, et al.
Publicado: (2007)

Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial
por: Taylor, Graham P, et al.
Publicado: (2006)

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort
por: Scarsi, Kimberly K., et al.
Publicado: (2016)

Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana
por: Powis, Kathleen M., et al.
Publicado: (2018)

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
por: Kumar, Princy N, et al.
Publicado: (2009)

Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
por: Alzate Angel, Juan Carlos, et al.
Publicado: (2017)

2507. Transmitted and Acquired NNRTI Resistance in the Philippines: Are Newer Generation NNRTIs a Viable Option?
por: Theresa Dungca, Nina, et al.
Publicado: (2019)

Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-Infected Ugandan Adults
por: Byakika-Tusiime, Jayne, et al.
Publicado: (2008)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Zidovudine.
por: Sperling, R
Publicado: (1998)

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
por: Rodriguez, Allan E, et al.
Publicado: (2010)

Development and validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets
por: Venkatesh, Palani, et al.
Publicado: (2012)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
por: Llibre, Josep M., et al.
Publicado: (2015)

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
por: Gitta, PK, et al.
Publicado: (2010)

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
por: Ross, L. L., et al.
Publicado: (2010)

Zidovudine-induced myopathy
por: Wiwanitkit, Viroj
Publicado: (2011)

Zidovudine Induced Hyperpigmentation
por: Premjith, Raveendran, et al.
Publicado: (2022)

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092
por: Owor, Maxensia, et al.
Publicado: (2021)

Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death
por: Heck, Carley J. S., et al.
Publicado: (2020)

HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission
por: Samuel, Reshmi, et al.
Publicado: (2016)

The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience
por: Erhabor, Osaro, et al.
Publicado: (2009)

Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks—A proof-of-concept study
por: Kahlert, C. R., et al.
Publicado: (2020)

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study
por: de Boissieu, Paul, et al.
Publicado: (2016)

Comparison of antibody responses against Mycobacterium tuberculosis antigen Rv0679c in tuberculosis patients from the endemic and non-endemic regions of the Beijing genotype: a case control study
por: Zhao, Jingge, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k1burlqo6ibl2dqghr7499ppr2